KRAS and ovarian carcinoma: Interestingly, we found that MI-136 treatment induced downregulation of KRAS signalling, whose constitutive activation is typically associated with low-grade ovarian carcinoma, endometrioid and mucinous ovarian tumours since these OC subtypes usually bear KRAS activating mutations [50].